🎉 M&A multiples are live!
Check it out!

ACADIA Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for ACADIA Pharmaceuticals and similar public comparables like Pharming, Vivoryon Therapeutics, and Benevolent AI.

ACADIA Pharmaceuticals Overview

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.


Founded

1993

HQ

United States of America
Employees

654

Website

acadia.com

Financials

LTM Revenue $988M

LTM EBITDA $197M

EV

$1.8B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ACADIA Pharmaceuticals Financials

ACADIA Pharmaceuticals has a last 12-month revenue of $988M and a last 12-month EBITDA of $197M.

In the most recent fiscal year, ACADIA Pharmaceuticals achieved revenue of $958M and an EBITDA of $100M.

ACADIA Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ACADIA Pharmaceuticals valuation multiples based on analyst estimates

ACADIA Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $726M $958M XXX XXX XXX
Gross Profit $507M $685M XXX XXX XXX
Gross Margin 70% 71% XXX XXX XXX
EBITDA -$67.8M $100M XXX XXX XXX
EBITDA Margin -9% 10% XXX XXX XXX
Net Profit -$216M -$61.3M XXX XXX XXX
Net Margin -30% -6% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

ACADIA Pharmaceuticals Stock Performance

As of April 15, 2025, ACADIA Pharmaceuticals's stock price is $15.

ACADIA Pharmaceuticals has current market cap of $2.5B, and EV of $1.8B.

See ACADIA Pharmaceuticals trading valuation data

ACADIA Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.8B $2.5B XXX XXX XXX XXX $1.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ACADIA Pharmaceuticals Valuation Multiples

As of April 15, 2025, ACADIA Pharmaceuticals has market cap of $2.5B and EV of $1.8B.

ACADIA Pharmaceuticals's trades at 1.8x LTM EV/Revenue multiple, and 9.0x LTM EBITDA.

Analysts estimate ACADIA Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ACADIA Pharmaceuticals and 10K+ public comps

ACADIA Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.8B XXX XXX XXX
EV/Revenue 1.9x XXX XXX XXX
EV/EBITDA 17.7x XXX XXX XXX
P/E 10.9x XXX XXX XXX
P/E/Growth -0.8x XXX XXX XXX
EV/FCF 11.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ACADIA Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ACADIA Pharmaceuticals Valuation Multiples

ACADIA Pharmaceuticals's NTM/LTM revenue growth is 11%

ACADIA Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.5M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, ACADIA Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ACADIA Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ACADIA Pharmaceuticals and other 10K+ public comps

ACADIA Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 32% XXX XXX XXX XXX
EBITDA Margin 10% XXX XXX XXX XXX
EBITDA Growth -248% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 21% XXX XXX XXX XXX
Revenue per Employee $1.5M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 32% XXX XXX XXX XXX
Opex to Revenue 83% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ACADIA Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ACADIA Pharmaceuticals M&A and Investment Activity

ACADIA Pharmaceuticals acquired  XXX companies to date.

Last acquisition by ACADIA Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . ACADIA Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ACADIA Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ACADIA Pharmaceuticals

When was ACADIA Pharmaceuticals founded? ACADIA Pharmaceuticals was founded in 1993.
Where is ACADIA Pharmaceuticals headquartered? ACADIA Pharmaceuticals is headquartered in United States of America.
How many employees does ACADIA Pharmaceuticals have? As of today, ACADIA Pharmaceuticals has 654 employees.
Who is the CEO of ACADIA Pharmaceuticals? ACADIA Pharmaceuticals's CEO is Ms. Catherine Owens Adams.
Is ACADIA Pharmaceuticals publicy listed? Yes, ACADIA Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of ACADIA Pharmaceuticals? ACADIA Pharmaceuticals trades under ACAD ticker.
When did ACADIA Pharmaceuticals go public? ACADIA Pharmaceuticals went public in 2004.
Who are competitors of ACADIA Pharmaceuticals? Similar companies to ACADIA Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ACADIA Pharmaceuticals? ACADIA Pharmaceuticals's current market cap is $2.5B
What is the current revenue of ACADIA Pharmaceuticals? ACADIA Pharmaceuticals's last 12-month revenue is $988M.
What is the current EBITDA of ACADIA Pharmaceuticals? ACADIA Pharmaceuticals's last 12-month EBITDA is $197M.
What is the current EV/Revenue multiple of ACADIA Pharmaceuticals? Current revenue multiple of ACADIA Pharmaceuticals is 1.8x.
What is the current EV/EBITDA multiple of ACADIA Pharmaceuticals? Current EBITDA multiple of ACADIA Pharmaceuticals is 9.0x.
What is the current revenue growth of ACADIA Pharmaceuticals? ACADIA Pharmaceuticals revenue growth between 2023 and 2024 was 32%.
Is ACADIA Pharmaceuticals profitable? Yes, ACADIA Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.